Viewing Study NCT01516918


Ignite Creation Date: 2025-12-25 @ 5:05 AM
Ignite Modification Date: 2025-12-26 @ 4:08 AM
Study NCT ID: NCT01516918
Status: COMPLETED
Last Update Posted: 2014-10-20
First Post: 2012-01-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Sponsor: Vertex Pharmaceuticals Incorporated
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module